表紙:サイトメガロウイルス (CMV) :疫学予測
市場調査レポート
商品コード
663472

サイトメガロウイルス (CMV) :疫学予測

Cytomegalovirus (CMV): Epidemiology Forecast to 2027

出版日: | 発行: GlobalData | ページ情報: 英文 55 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円
サイトメガロウイルス (CMV) :疫学予測
出版日: 2018年06月20日
発行: GlobalData
ページ情報: 英文 55 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本) におけるサイトメガロウイルス (CMV) について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 サイトメガロウイルス (CMV) :エグゼクティブサマリー

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向と過去の動向
    • HIV感染患者におけるCMV疾患
    • SOT患者におけるCMV疾患
    • Allo-HSCT 患者におけるCMV疾患
    • 先天的CMV疾患
  • 予測手法
    • 情報源
    • 予測の前提条件と手法
  • CMVの疫学予測
    • CMV診断事例数
    • CMVの発症事例 (年齢別)
    • CMVの発症事例 (性別)
    • CMV 診断事例数:暴露人口別
    • HIV-CMV
    • SOT患者
    • SOT-CMV
    • HSCT患者
    • HSCT-CMV
    • 先天的CMVの診断事例
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for CMV 8

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of CMV, Both Sexes, All Ages, 2017 and 2027 5
  • Figure 2: Age-Standardized Diagnosed Incidence of CMV Disease, All Ages, 2017 9
  • Figure 3: Case Flow Map 11
  • Figure 4: Sources Used and Not Used for Calculations of Diagnosed Incident Cases of HIV-CMV 12
  • Figure 5: Sources Used and Not Used for Calculations of SOT Patients 13
  • Figure 6: Sources Used and Not Used for Calculations of Diagnosed Incident Cases of SOT-CMV 14
  • Figure 7: Sources Used and Not Used for Calculations of Allo-HSCT Patients and Diagnosed Incident Cases of HSCT-CMV 15
  • Figure 8: Sources Used and Not Used for Calculations of Live Births and cCMV Cases 16
  • Figure 9: Diagnosed Incident Cases of CMV, 7MM, Men and Women, All Ages, 2017 29
  • Figure 10: 7MM, Age-Specific Diagnosed Incident Cases of CMV Disease, Men and Women, 2017 30
  • Figure 11: 7MM, Sex-Specific Diagnosed Incident Cases of CMV Disease, All Ages, 2017 31
  • Figure 12: 7MM, Diagnosed Incident Cases of CMV Disease by Population at Risk, Men and Women, All Ages, 2017 32
  • Figure 13: 5EU and Japan, Diagnosed Incident Cases of HIV-CMV, Men and Women, All Ages, 2017-2027 33
  • Figure 14: US, Diagnosed Incident Cases of HIV-CMV, Men and Women, All Ages, 2017-2027 33
  • Figure 15: 7MM, SOT Patients, Men and Women, All Ages, 2017-2027 34
  • Figure 16: 7MM, Diagnosed Incident Cases of SOT-CMV, Men and Women, All Ages, 2017-2027 35
  • Figure 17: 7MM, Allo-HSCT Patients, Men and Women, All Ages, 2017-2027 36
  • Figure 18: 7MM, Diagnosed Incident Cases of HSCT-CMV, Men and Women, All Ages, 2017-2027 37
  • Figure 19: 5EU and Japan, Diagnosed Incident Cases of cCMV, Men and Women, All Ages, 2017-2027 38
  • Figure 20: US, Diagnosed Incident Cases of cCMV, Men and Women, All Ages, 2017-2027 39
目次
Product Code: GDHCER188-18

The report "Cytomegalovirus (CMV): Epidemiology Forecast to 2027", report provides an overview of the risk factors, comorbidities, and global and historical trends for Cytomegalovirus (CMV) disease among HIV, SOT, allo-HSCT, and newborn populations in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).

Cytomegalovirus (CMV) is a common virus belonging to the Herpesviridae family. CMV is present in up to 60% of adults in high-income countries and up to 100% of adults in low- and middle-income countries. In individuals with healthy immune systems, Cytomegalovirus (CMV) infections are typically asymptomatic, and the virus establishes a lifelong latent infection. Certain populations, such as people living with human immunodeficiency virus (HIV), solid organ transplant (SOT) patients, allogeneic hematopoietic stem cell transplant (allo-HSCT) patients, and infants infected in utero, are vulnerable to symptomatic disease caused by primary CMV infections or reactivation. CMV disease may also occur in critically ill immunocompetent patients (Siciliano et al., 2014). Depending on the population, CMV disease can present as end-organ disease (infection and symptoms in lung, gastrointestinal (GI) tract, liver, retina, or other organs), CMV syndrome (fever, fatigue, leukopenia, and/or thrombocytosis), or congenital CMV (cCMV) (symptoms ranging from mild manifestations to premature birth and neurologic sequelae.

In 2017, there were 9,691 diagnosed incident cases of Cytomegalovirus (CMV) disease in the 7MM. The US had the most cases (5,885), while Japan had the fewest (271). Epidemiologists forecast that the number of CMV cases in the 7MM will increase to 10,704 in 2027, at an Annual Growth Rate (AGR) of 1.05%. All countries besides Germany are expected to see an increase in CMV cases. HIV patients made up the greatest burden of CMV cases in the 7MM in 2017 (3,734 cases), followed closely by SOT patients (3,696 cases).cCMV accounted for the fewest cases (979).

The report includes a 10-year epidemiological forecast for diagnosed incident cases of CMV disease segmented by population at risk, sex, and age (in 10-year age groups beginning at ages 0-10 years and ending at ages 80 years and older) in these markets. In addition, this report includes a 10-year forecast for SOT and allo-HSCT patient populations in the 7MM.

Scope

  • The Cytomegalovirus (CMV) Epidemiology Forecast Report provides an overview of the risk factors and global trends of CMV in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report provides an overview of the risk factors, comorbidities, and global and historical trends for CMV disease among HIV, SOT, allo-HSCT, and newborn populations in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of CMV disease segmented by population at risk, sex, and age (in 10-year age groups beginning at ages 0-10 years and ending at ages 80 years and older) in these markets. In addition, this report includes a 10-year forecast for SOT and allo-HSCT patient populations in the 7MM.
  • The CMV epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The CMV Epidemiology Forecast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CMV market.
  • Quantify patient populations in the global CMV market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CMV therapeutics in each of the markets covered.
  • Understand magnitude of CMV population by population at risk.

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 CMV: Executive Summary 4

  • 2.1 Related Reports 5
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 7
  • 3.3 Global and Historical Trends 8
    • 3.3.1 CMV Disease in Diagnosed Prevalent HIV Patients 9
    • 3.3.2 CMV Disease in SOT Patients 10
    • 3.3.3 CMV Disease in Allo-HSCT Patients 10
    • 3.3.4 Congenital CMV Disease 11
  • 3.4 Forecast Methodology 11
    • 3.4.1 Sources 12
    • 3.4.2 Forecast Assumptions and Methods 17
  • 3.5 Epidemiological Forecast for CMV (2017-2027) 28
    • 3.5.1 Diagnosed Incident Cases of CMV 28
    • 3.5.2 Age-Specific Incident Cases of CMV 29
    • 3.5.3 Sex-Specific Diagnosed Incident Cases of CMV 30
    • 3.5.4 CMV Diagnosed Incident Cases by Population at Risk 31
    • 3.5.5 HIV-CMV 32
    • 3.5.6 SOT Patients 34
    • 3.5.7 SOT-CMV 35
    • 3.5.8 HSCT Patients 36
    • 3.5.9 HSCT-CMV 37
    • 3.5.10 Diagnosed Incident Cases of Congenital CMV 38
  • 3.6 Discussion 39
    • 3.6.1 Epidemiological Forecast Insight 39
    • 3.6.2 Limitations of Analysis 40
    • 3.6.3 Strengths of Analysis 40

4 Appendix 42

  • 4.1 Bibliography 42
  • 4.2 About the Authors 52
    • 4.2.1 Epidemiologist 52
    • 4.2.2 Reviewers 52
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 53
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 53
  • 4.3 About GlobalData 54
  • 4.4 Contact Us 54
  • 4.5 Disclaimer 54